3Williamson MP,Williams DH. Structure revision of the antibiotic vancomycin, the use of nuclear overhauser effect difference spectroscopy. J Am Chem Soc, 1981,103:6580-6585.
4Sievert DM,Bouhon ML,Stoltman G,et al. Staphylococcus au- reus to vancomycin United States 2002. MMWR,2002,5I (26): 567.
5Chambers HF. Penicillin-binding protein-mediated resistance in pneumococcal and staphylococci. J Infect Dis, 1999,179 Suppl 2: 353-359.
7Pfehz RF,Singh VK,Schmidt JL,et al. Characterization of pas- sage-selected vancomycin resistant staphylococcus aureus strains of diverse parental background. Antimicrobial Agents Chem Other,2000, 44(2) :294-303.
8Eggert US,Ruiz N,Kahne D,et al. Genetic basis for activity dif- ferences between vancomycin and glycolipid derivatives of van- comycin. Science, 2001,294: 361-364.
9Jeffrey M, Steven LC, Boger DL, et al. Synthesis and evaluation of vancomycin and vancomycin aglycon analogues that bear modifi- cations in the residue asparagine. Bioorg Med Chem Lett,2002, 12:1319- 1322.
10Jain RK,Trias J,Ellman JA,et al. D-Ala-D-A la binding is not required for the high activity of vancomycin dimcrs against van- comycin resistant enterococci. J Am Chem Soc,2003,125:8740- 8741.
8Livermore D M. Introduction : the challenge of muhiresistance [J]. lnt J Antimicrob Agents, 2007,29(3) :S1-S7.
9Li X Z, Nikaido H. Efflux-mediated drug resistance in bacteria [J]. Drugs, 2004, 64 (2) :159-204.
10Viveiros M, Martins M, Couto I, et al. New methods for the identification of effiux mediated MDR bacteria, genetic assessment of regulators and efflux pump constituents, characterization of efflux systems and screening for inhibitors of efflux pumps[J]. Curr Drug Targets, 2008, 9(9) :760-778.
